

Table S1 Characterization data monovalent anti-PcrV Nanobodies

	P3X63 cell death assay			Epitope binning			
Nanobody	pIC50 (M)	Efficacy (%) [†]	Off-rate (s ⁻¹)	Nanobody bin (ELISA)	Nanobody bin (SPR)	Fab1A8 competition	Sequence
1E11	7.6	58	3.5 x 10 ⁻⁴	bin 1	bin 1	No	EVQLVESGGGLVQPGGSLRLSCAASGSTRSVNPMAWFRQAPGRQ REWVATISRSGYATYADSVKGRFTISGDNAKSSVYLQMNSLKPED TAVYYCVTGTYWGQGTIVTVSS
2B02	5.8	100	3.7 x 10 ⁻⁴	bin 1	ND	No	EVQLVESGGGLVQPGDSLRLSCAASGRILSINNMVWYRQAPGKQ RELVAHITSSGSTGYADSVKGRFTISRDNAKNTFYLQMTNLNPED TAVYYCNCWVSSDSNAPLKNYWGQGTQTVSS
2B10	6.2	100	1.8 x 10 ⁻⁴	bin 1	ND	No	EVQLVESGGGLVQPGGSLRLSCAASGSIFSINNMGWYRQAPGKQ RELVTVVTSNLITTYADSVKGRFTISRDNAKNTVYLQMNSLKPED TAVYYCNAWARSVGSPVYSQFWGQGTIVTVSS
2G09	8.4	55	1.0 x 10 ⁻³	bin 1	ND	No	EVQLVESGGGLVQPGGSLRLSCAASGSFGDNYELYAMTWFRQAP GERRDFVASVTGDGSTSYADSVKDRFTISRDNAKKLMYLMQNSL KPEDTAVYYCRLNNYWGQGTIVTVSS
3B11	< 6.0 [†]		2.7 x 10 ⁻³	ND	bin 1 & 2	No	EVQLVESGGGLVQAGGSLRLSCAASGFTDDYVIGWFRQAPGKE REGVSCISRLDGRTYYTDSVKGRFTISSLNAKNTVYLQMNSLKPE DTAVYYCALEPRYTDYYPVHELYWGQGTQTVSS
3E10	7.3	94	1.5 x 10 ⁻³	ND	bin 1 & 2	Yes	EVQLVESGGGLVQAGGSLRLSCASHTFSSYTMGWFRQAPGKE REFVAAMTRSGFNTHYSDSVKGRFTISRDNTKITMALQM NSLPEDTAVYYCTTGRGLTSYVANFWGQGTQTVSS
4C03	< 5.3 [†]		6.8 x 10 ⁻³	ND	bin 1	No	EVQLVESGGGLVQAGGSLRLSCVISASTVRNYDMGWFRQAPGKE REFVAAIDWSGGSTRYADSVKGRFTVSRDNAKNTVYLQMNSLKP EDTAVYYCVAAGFYNNYLRTAPNDWNYWGQGTIVTVSS
4G10	7.0	100	1.3 x 10 ⁻⁴	ND	bin 1	No	EVQLVESGGGLVQAGGSLRLSCVISEDGVRYDMGWFRQAPGKE REFVATINWSGGSTNYADSVKGRFTVSRDNAKNTMYLQMDSLKP EDTAVYYCVAAGFYNNYLRTAPNDWWDWGQGTQTVSS
5E02	7.4	100	5.7 x 10 ⁻⁴	ND	bin 2	Yes	EVQLVESGGGLVQPGGSLRLSCAASGITLDSIAICWFRQAPGKERE GVSCSRGSDGSTYYADSVKGRFTISRVNAKNTVYLQMNSLKPED TAVYYCAAAPSIFYSGGYFPSGMWDWGKGTQTVSS
5H01	8.2	100	4.9 x 10 ⁻⁵	bin 2	bin 2	Yes	EVQLVESGGGLVQPGGSLRLSCAASGSTDYYAIGWFRQAPGKE REGVCTSNSGSTYYGGSVKGRFTASRDNAKNTVYLQMNSLRPE DTAVYYCVATIGCATLGTLDVQRYYYRGQGTQTVSS
6B05	6.4	100	1.8 x 10 ⁻⁴	bin 1	ND	No	EVQLVESGGGLVQPGGSLRLSCAASGSIFSINTMGWYRQAPGKQR

							ELVSTITSNLVPHYADSVQGRFTISRDNARNTVYLQMNSLKPKDT AHYYCNAWARSSGATPYTNWQGQTLTVSS
7C10	7.4	100	8.2×10^{-4}	bin 1 & 2	ND	Yes	EVQLVESGGGLVQAGGSLRLSCTASGRTLSSYTMGWFRQAPGTE REFVAAMTRSGFNTYYADSVKGRFTISRDSTENTMALQMSSLKPE DTAVYYCTAGRGLTSYRADYWQGQTLTVSS
7E09	NB		4.0×10^{-4}	bin 3	ND	No	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYIMGWFRQAPGKA REFVADITWGQRPYYADSVKGRFTISRDNAKNTVYLEMNSLKPE DTAVYYCAADLGVVIREEHAYWGQGQTLTVSS
10C05	< 6.0 [†]		6.0×10^{-4}	bin 1	ND	No	EVQLVESGGGLVQPGGSLRLSCAASGSIFSINTMGWYRQAPGKQR DLVASITMNQVPNYADSVQGRFTISRDNRNVRNTVHLQMNAVKPED TADYFCNAWRSSGASPYTNWQGQGTQVTVSS
11B09	7.0	100	4.8×10^{-3}	bin 1	ND	No	EVQLVESGGGLVQAGGSLRLSCAASRLTFNHYNMGWFRQAPGK ERERVAEVTWSGDKIYYYVDSDKRFTISRDNTPNPVLYLQMNS LKPEDTAVYYCATAPRGLPYANGYWQGQGTQVTVSS
12B02	NB		4.4×10^{-5}	ND	bin 4	No	EVQLVESGGGLVQPGGSLRLSCAASGFSLGVFAIGWFRQAPGKER EGVSCIDSSDGRRTTYADSVKGRFTISRDNAKNTVYLQMNSLKPED TAVYYCATDIETDVCSCAGWGFWGQGTQVTVSS
13F07	< 5.0 [†]		2.0×10^{-3}	bin 3	bin 3	No	EVQLVESGGGLVQAGGSLRLSCAASGNTFSTNPYMYWYRQAEKGK QRELVASISSRGITNYADSVRGRFSISRDNTKDTVYLQMNSLKPED TAVYYCRLASLSSGTVYWGKGTQVTVSS
14B10	< 5.5 [†]		9.2×10^{-4}	ND	bin 1	No	EVQLVESGGGLVQPGGSLRLSCAASGRIFSINNMGWYHQAPGKQ RELVATITMNGITTYADSVKGRFTISRDNAKNTVYLQMNSLKPED TAVYYCSCWVRSSGGDPYRDYWQGQGTQVTVSS
14E10	< 5.5 [†]		6.0×10^{-4}	bin 1	ND	No	EVQLVESGGGLVQPGGSLRLSCAASGRIFSINTMGWYRQAPGKQ RELVAGVTINAITNYADSVKGRFTISRDNAKNTVWLQMNSLKPE DTAVYYCHAWARSSGSAPYSQNWGQGTQVTVSS

[†]: Efficacy (% inhibition of *Pa*-mediated cell death) is expressed relative to the assay window spanned by the condition in absence of *Pa* (no *Pa*-mediated cell death) and the condition in the presence of *Pa* without blocking Nanobody (no inhibition of *Pa*-mediated cell death) (see also Table 1 and Fig. 6A).

ND: not-determined

NB: No blocking observed in tested concentration range

[†]: No complete dose response curve obtained in tested concentration range